Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.60 |
| ▸ | CTSL | P07711 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | KYNU | Q16719 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | ELANE | P08246 | 2/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5192939 | 1.00 | TRPM8 (0.60) | TRPM8CTSLCTSSATMCTSB | |
| SCHEMBL9656912 | 0.91 | CTSL (0.56) | TRPM8CTSLCTSSATMCTSB | |
| SCHEMBL6558624 | 0.91 | CTSL (0.56) | TRPM8CTSLCTSSATMCTSB | |
| SCHEMBL9656905 | 0.91 | CTSL (0.56) | TRPM8CTSLCTSSATMCTSB | |
| SCHEMBL4399079 | 0.91 | CTSL (0.56) | TRPM8CTSLCTSSATMCTSB | |
| SCHEMBL9789291 | 0.91 | CTSL (0.56) | TRPM8CTSLCTSSATMCTSB | |
| SCHEMBL5196368 | 0.90 | TRPM8 (0.58) | TRPM8CTSLCTSSATMCTSB | |
| SCHEMBL5195885 | 0.89 | TRPM8 (0.57) | TRPM8CTSLCTSSATMCTSB | |
| SCHEMBL28892051 | 0.88 | TRPM8 (0.62) | TRPM8CTSLCTSSATMCTSB | |
| SCHEMBL10535601 | 0.88 | TRPM8 (0.62) | TRPM8CTSLCTSSATMCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829568-B1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2017-05-11 | — | — | US | disclosed |
| US-9540394-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20160130281-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2016-05-12 | — | — | US | disclosed |
| EP-2948461-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | Entasis Therapeutics Limited (GB) | 2015-12-02 | — | — | EP | disclosed |
| US-9187495-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20150203513-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2015-07-23 | — | — | US | disclosed |
| US-8889671-B2 | Compounds and methods for treating bacterial infections | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| WO-2014114929-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | TRPM8 2123/4885CTSL 524/4885CTSS 661/4885 |
| US-20160130281-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | TRPM8 2123/4885CTSL 524/4885CTSS 661/4885 |
| US-20150203513-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | TRPM8 2123/4885CTSL 524/4885CTSS 661/4885 |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | TRPM8 2123/4885CTSL 524/4885CTSS 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.